March 14, 2025 7:58am

Negativity, rants, go back to fundamentals as most of the earnings are over and yet pipelines are advancing

Induced volatility is killing share pricing, rebound needed as a Friday factor

Pre-open Indications: 5 Positive and 1 Negative Indications

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Thursday’s night’s … RegMed Investors (RMi) Closing Bell: econs take their toll … https://www.regmedinvestors.com/articles/13839

 

Friday: The pre-open Dow futures are UP +0.58% or (+238 points), the S&P futures are UP +0.88% or (+44 points) and the Nasdaq futures are UP +1.17% or ( +224 points)

  • Stock futures rose Friday, 3/14
  • European markets opened higher,
  • Asia-Pacific markets mostly rose

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Thursday, the S&P 500 dropped -1.38% or 77.77 points, The Dow slid -1.29% or -537.36 points while the Nasdaq -1.95% or 345.43 points.

The Dow is on track for its 2nd straight losing week and worst weekly decline since June 2022. This would be the 4th negative week in a row for the S&P 500 and Nasdaq

Economic Data Docket: Consumer sentiment (prelim)

 

Q1/25:  March sessions with 4 positive and 6 negative closes

  • February – 1 holiday, 11 negative and 8 positive closes
  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty.

Although Positive Indications: pre-open

  • AxoGen (AXGN) closed down -$0.29 with a positive +$0.53 or +3.09%
  • Beam Therapeutics (BEAM) closed down -$2.36 with a positive +$0.59 or +2.35%
  • Blueprint Medicine (BPMC) closed down -$0.66 with a positive +0.94 or +1.05%
  • Moderna (MRNA) closed down -$0.71 with a positive +$0.55 or +11.60%
  • Vericel (VCEL) closed down -$0.42 with a positive +$1.25 or +2.75%

 

Although Negative Indication: pre-open

  • Ionis Pharmaceuticals (IONS) closed down -$0.51 with a negative -$0.37 or -1.12%

 

The BOTTOM LINE: New week, the 2nd of March and 4th session with a negative close following a Wednesday and Tuesday’s positive close following Monday’s negative sector close.

  • Last Friday, 3/7 – the 5th NEGATIVE session in the week intermingled by 1 POSITIVE (Wednesday) close in a new month of March … so, what moves stock pricing?
  • As I have written, “uncle algo and his trading dwarfs” will determine the heights or lows of share pricing”

March to date:

  • 3/13 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 3/12 – Wednesday closed positive with 25 positive, 9 negative and1 flat
  • 3/11 - Tuesday closed positive with 23 positive, 11 negative and 1 flat
  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 – Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3/4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

Reiterating, “I think it's important just to take a step back, focus on the fundamentals, be selective. I mean, this has definitely been a “sucky” January and February from a stock-picker standpoint given the up/downs. And so, I am relatively neutral across today/Friday’s equity strategy.

  • Reiterating, “Take the emotion out of the sector, think of the reality of the “plays” that exist of who’s really buying.”

It’s STILL earnings season “sparking” a quarterly life crisis…

  • Cell and Gene therapy earnings continue to be important; LPS (loss per share), revenue uplifts and lags, clinical progress with some program uncertainty, a dearth all followed by estimate misses
  • The coming batch of quarterly earnings will provide last years, FY2024’s LPS (loss-per-share), some EPS, consensus meets and non-greets, cash positions, runways and partner status for investors

Earnings are here … from Q4/24 and FY24 … my view will follow, has been busy and personally eventful!

  • Cellectis SA (CLLS) – Thursday, 3/13
  • Generation Bio (GBIO) – Thursday, 3/13
  • Regenxbio (RGNX) – Thursday, 3/13
  • Sangamo Therapeutics (SGMO), Monday, 3/17

Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject.

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.